Patent assignee · DE · COMPANY

CureVac AG

101Patents
100Active
101Granted
62Portfolio score

Filing activity: Dec 5, 2003 → Dec 9, 2021 · 4 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8217016B2 Application of mRNA for use as a therapeutic agent for tumorous diseases Human Necessities 177 Expired
US8383340B2 Method for purifying RNA on a preparative scale by means of HPLC Chemistry; Metallurgy 126 Active
US9669089B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen Emerging Cross-Sectional Technologies 92 Active
US10188748B2 Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions Emerging Cross-Sectional Technologies 65 Active
US9623095B2 Vaccination in newborns and infants Emerging Cross-Sectional Technologies 64 Active
US9572874B2 Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof Human Necessities 63 Active
US8968746B2 Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation Emerging Cross-Sectional Technologies 59 Active
US9447431B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein Chemistry; Metallurgy 57 Active
US8703906B2 Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids Human Necessities 57 Active
US9155788B2 Application of mRNA for use as a therapeutic against tumour diseases Human Necessities 56 Active
US9616084B2 Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids Human Necessities 56 Active
US9688729B2 Respiratory syncytial virus (RSV) vaccine Chemistry; Metallurgy 53 Active
US9683233B2 Artificial nucleic acid molecules for improved protein or peptide expression Chemistry; Metallurgy 51 Active
US9226959B2 Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant Emerging Cross-Sectional Technologies 45 Active
US11241493B2 Coronavirus vaccine Chemistry; Metallurgy 43 Active
US10293058B2 RNA containing composition for treatment of tumor diseases Emerging Cross-Sectional Technologies 41 Active
US11078247B2 RNA encoding a therapeutic protein Chemistry; Metallurgy 38 Active
US9234013B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein Emerging Cross-Sectional Technologies 37 Active
US10988754B2 Nucleic acid molecules Emerging Cross-Sectional Technologies 36 Active
US10912826B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen Emerging Cross-Sectional Technologies 34 Active
US9655955B2 Application of mRNA for use as a therapeutic against tumour diseases Human Necessities 34 Active
US9839697B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein Emerging Cross-Sectional Technologies 32 Active
US10729654B2 Dry powder composition comprising long-chain RNA Human Necessities 32 Active
US11179337B2 Dry powder composition comprising long-chain RNA Human Necessities 31 Active
US10517827B2 Dry powder composition comprising long-chain RNA Human Necessities 31 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.